Adult Dosing

Increased IOP in patients with ocular hypertension or open-angle glaucoma

• 1 drop in affected eye(s) tid

Pediatric Dosing

Increased IOP in patients with ocular hypertension or open-angle glaucoma

• 1 drop in affected eye(s) tid

[Outline]

• Adult Dosing
• Pediatric Dosing

• Treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma

• Hypersensitivity to any of the ingredients/class of the product
• Severe renal impairment (CrCl <30 mL/min)
• Co-administration with oral carbonic anhydrase inhibitors

• N/A

Renal Dose Adjustment (Based on CrCl)

• Severe renal impairment (<30 mL/min): Contraindicated

Hepatic Dose Adjustment

• Hepatic impairment: Use cautiously; dose adjustments not defined

See Supplemental Patient Information

• Rare occasion of fatalities have occurred that include Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias
• Sensitization may recur on re-administration of the drug irrespective of the route of administration; discontinue the treatment if such reactions occur
• Patients with acute angle-closure glaucoma may require therapeutic interventions along with ocular hypotensive agents
• Not recommended in patients with severe renal impairment
• Local ocular adverse effects, primarily conjunctivitis and lid reactions may occur, which resolve upon discontinuation of therapy; evaluate patients before restarting the therapy
• Bacterial keratitis may result with the use of multiple-dose containers, which may be contaminated by patients having concurrent corneal disease or a disruption of the ocular epithelial surface
• Choroidal detachment may be caused with administration of the drug after filtration procedure

Cautions: Use cautiously in

• Hepatic impairment
• Patients with low endothelial cell counts
• Hypersensitivity to sulfonamides

Supplemental Patient Information

• Do not touch the tip of the container to the eye or surrounding area
• If more than one ophthalmic drug is used, administer the drugs at least 10 minutes apart
• Remove contact lenses prior to administration of the drug and reinsert 15 minutes after instillation
• Advise patients to promptly seek their physician’s advice regarding the continued use of multi-dose container if they develop an intercurrent ocular condition or have ocular surgery

Pregnancy Category:C

Breastfeeding: Safety unknown; is unlikely to adversely affect the breastfed infant. To substantially diminish the amount of drug reaching the breastmilk, place pressure over the tear duct by the corner of the eye for 1 minute or more and remove the excess solution with an absorbent tissue. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 3 March 2011). Manufacturer recommends discontinuation of nursing or discontinuation of therapy by analyzing risk and benefit ratio in the nursing mothers.

• EENT: Ocular burning, stinging, discomfort, blurred vision, ocular allergy, eye redness, tearing, dryness, conjunctivitis, photophobia, choroidal detachment, photophobia, dry eyes, punctate keratitis, eyelid rashes
• GI: Bitter taste
• CV: Angioedema
• DERM: Stevens-Johnson syndrome, toxic epidermal necrolysis
• HEMA: Agranulocytosis, aplastic anemia, blood dyscrasias
• CNS: Dizziness, headache
• HEPA: Hepatic necrosis
• RESP: Bronchospasm

• Carbonic anhydrase inhibitor; it decreases aqueous humor secretion, probably by delaying the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport resulting in decreased IOP
• Metabolism: other; CYP450: unknown; N-desethyl metabolite
• Excretion: Urine (unchanged form and active metabolite)
• Half-life: 4 months

US Trade Name(s)

• Trusopt

US Availability

dorzolamide (generic)

• OPTH SOLN: 2%

Trusopt

• OPTH SOLN: 2%

Canadian Trade Name(s)

• Trusopt
• Trusopt (preservative-free)

Canadian Availability

dorzolamide (generic)

• OPTH SOLN: 2%

Trusopt

• OPTH SOLN: 2%

Trusopt (preservative-free)

• OPTH SOLN: 2%

UK Trade Name(s)

• Trusopt

UK Availability

dorzolamide (generic)

• OPTH SOLN: 20 mg/mL

Trusopt

• OPTH SOLN: 20 mg/mL

Australian Trade Name(s)

• Trusopt

Australian Availability

Trusopt

• OPTH SOLN: 2%

[Outline]

Ophthalmic

Ophthalmic Glaucoma Agents

Carbonic Anhydrase Inhibitor

Pricing data from www.DrugStore.com in U.S.A.

• Trusopt 2 % SOLN [Bottle] (MERCK SHARP & DOHME)
  10 % = $79.25
  30 % = $215.09

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.